LCM
JAZZ icon

Logan Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Logan Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$485K Buy
+2,568
New +$449K 0.02% 246

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Logan Capital Management's JAZZ Position: Q1 2026 in Review

Logan Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 2,568 shares — an estimated $449K sold.

Logan Capital Management first reported a position in JAZZ in Q2 2015 and held it in 28 quarters. The position peaked at $671K in Q1 2022. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Logan Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Logan Capital Management sold 2,568 Jazz Pharmaceuticals shares in Q1 2026, an estimated $449K.
  • Logan Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2015 and held it in 28 quarters.
  • Logan Capital Management's Jazz Pharmaceuticals position peaked at $671K in Q1 2022.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Logan Capital Management's 13F filing for Q1 2026, filed 8 May 2026.